THERAPEUTIC EFFECT OF DOXOPHYLLINE IN PATIENTS WITH POST-COVID RESPIRATORY SYNDROME
DOI:
https://doi.org/10.34921/amj.2023.1.005Keywords:
long-term COVID (Long COVID), chronic COVID (Chronic COVID), doxofyllineAbstract
The article provides information about a study conducted to investigate the efficacy of doxophylline in post-COVID respiratory syndrome. The study was conducted on an outpatient basis at the Educational and Therapeutic Clinic of the Azerbaijan Medical University for 3 months in 2021-2022. The study included 47 patients with laboratory-confirmed COVID-19 pneumonia (PCR or rapid antigen test) and X-ray 4-12 weeks before the examination. In addition to general instrumental examinations, the intensity of cough was determined in patients - a questionnaire for assessing the severity of cough (Zhan W.), a modified dyspnea scale of the Medical Research Council and spirometry (FEV1 -ANHT1, EF, Tiffno index) examination. In accordance with the purpose of the work, post-COVID respiratory syndrome was confirmed in patients based on anamnestic-questionnaire scales and a spirometric examination performed at the beginning of treatment. After examination, all patients were prescribed doxofillin (Puroxan) 400 mg 2 times a day for 2 weeks. And for some patients who did not have a positive clinical and/or spirometric result, treatment was extended up to 8 weeks. During the study, all patients taking doxophylline showed a significant decrease in the intensity of cough and improvement in respiratory parameters. In conclusion, it can be considered appropriate to administer doxofylline at a dose of 400 mg to patients to improve respiratory parameters in post-COVID respiratory syndrome.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Azerbaijan Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.